Kerala Ayurveda reported a consolidated revenue of Rs 145.36 crore for FY 2025-26, up from Rs 122.15 crore last year. Despite the growth, the company posted a net loss of Rs 16.32 crore, citing rising interest costs and growth investments. Management has outlined an ambitious roadmap to reach Rs 200 crore in revenue and achieve EBITDA break-even by January 2027. Additionally, the board approved a Rs 13.71 crore preferential share issue to promoters to reduce debt.
Kerala Ayurveda FY26 Results and Growth Roadmap
Total Revenue: Rs 145.36 crore | Net Loss: Rs 16.32 crore
Reader Takeaway: Increasing revenue shows strong market demand, but persistent losses and auditor qualifications require careful monitoring.
What just happened
Kerala Ayurveda Limited has published its FY 2025-26 Annual Report, revealing a year of top-line growth coupled with bottom-line challenges. The company clocked a consolidated income of Rs 145.36 crore, a significant improvement from the previous year's Rs 122.15 crore. However, net losses widened to Rs 16.32 crore from Rs 13.96 crore, primarily driven by higher interest expenses on working capital loans and sustained expansion costs.
Why this matters
The company is signaling a transition phase. Management has set a formal goal to reach Rs 200 crore in consolidated revenue by FY 2026-27, with a specific milestone to achieve operating EBITDA break-even by January 2027. This reflects a shift in strategy from aggressive investment to operational efficiency and cash flow generation.
Fundraising and Corporate Moves
To strengthen its balance sheet, the board approved a preferential issue of 720,000 equity shares to promoter group entity Katra Holding Private Limited at Rs 190.37 per share. This Rs 13.71 crore infusion is earmarked for partially adjusting existing unsecured loans. Furthermore, the company completed the acquisition of the remaining 26% stake in Ayurvedagram Heritage Wellness Centre, moving to full ownership of the subsidiary.
Risks to watch
Shareholders should note the Statutory Auditor’s 'Qualified Opinion' regarding internal financial controls. Specifically, auditors flagged deficiencies in reconciling statutory dues and related-party transaction monitoring. While management is taking corrective actions, these governance aspects remain a point of oversight.
What to track next
Investors should monitor quarterly margin improvements and the effectiveness of the cost-optimization measures. Success in hitting the January 2027 EBITDA target will be the key indicator of whether the business transformation is yielding sustainable financial results.